Results 51 to 60 of about 12,561 (177)

Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis

Scientific Reports
Portal vein thrombosis (PVT) worsens the long-term prognosis of patients with cirrhosis; however, the optimal treatment remains to be determined. Reports on the efficacy of direct oral anticoagulants are increasing, and further evidence is needed ...
Tomoko Tadokoro, Joji Tani, Takushi Manabe, Kei Takuma, Mai Nakahara, Kyoko Oura, Shima Mimura, Koji Fujita, Takako Nomura, Asahiro Morishita, Hideki Kobara, Takashi Himoto, Masafumi Ono, Tsutomu Masaki   +13 more
doaj   +1 more source

Comparative treatment effects of direct oral anticoagulants versus warfarin for nonvalvular atrial fibrillation in clinical practice vary over time due to channelling

British Journal of Clinical Pharmacology, EarlyView.
Aim Temporal shifts in patient characteristics can influence comparative treatment effects within a certain indication. We investigated patient characteristics and comparative effectiveness and safety for direct oral anticoagulants (DOACs) and warfarin over the time period where DOACs replaced warfarin as preferred stroke prophylaxis in patients with ...
Raoul B. L. J. van den Hemel, Aernoud T. L. Fiolet, Magdalena A. Gamba, Patrick C. Souverein, Olaf H. Klungel, Lourens T. Bloem, Sophie H. Bots   +6 more
wiley   +1 more source

The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation

Атеротромбоз, 2020
Edoxaban is a selective direct factor Xa inhibitor. Edoxaban in a dose of 60 mg per day is an effective and safe option in the prevention of thromboembolic complications in patients with nonvalvular atrial fibrillation, including in combination therapy ...
O. O. Shakhmatova
doaj   +1 more source

Pulmonary Embolism—A Century of Progress

ANZ Journal of Surgery, EarlyView.
Reviews a century of progress in the diagnosis, prevention, and management of pulmonary embolism; from the first successful surgical embolectomy in 1924 to advanced imaging, pharmacological thromboprophylaxis, and treatment. In the 21st century, advances include catheter‐directed thrombolysis or mechanical thrombectomy under decision‐making guidance of
D. A. Watters
wiley   +1 more source

Point-of-care testing of coagulation in patients treated with edoxaban

, 2020
Edoxaban, alongside other direct oral anticoagulants (DOAC), is increasingly used for prevention of thromboembolism, including stroke. Despite DOAC therapy, however, annual stroke rate in patients with atrial fibrillation remains 1-2%. Rapid exclusion of
Spencer, Charlotte, Peter, Andreas, Birschmann, Ingvild, Kuhn, Joachim, Poli, Sven, Stefanou, Maria-Ioanna, Bombach, Paula, Härtig, Florian, Ebner, Matthias, Hörber, Sebastian, Sonnleitner, Matthias, Mengel, Annerose, Ziemann, Ulf   +12 more
core   +1 more source

Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital

Journal of Pharmaceutical Health Care and Sciences, 2020
Background The anticoagulant edoxaban is used clinically at doses of 30–60 mg/day; however, we experienced a patient who had taken an overdose of edoxaban of 750 mg.
Koichiro Adachi, Jumpei Tuchiya, Satoru Beppu, Kei Nishiyama, Makiko Shimizu, Hiroshi Yamazaki   +5 more
doaj   +1 more source

Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution

CPT: Pharmacometrics & Systems Pharmacology, 2023
This study aimed to develop a physiologically‐based pharmacokinetic pharmacodynamic (PBPK/PD) parent‐metabolite model of edoxaban, an oral anticoagulant with a narrow therapeutic index, and to predict pharmacokinetic (PK)/PD profiles and potential drug ...
Ruijuan Xu, Wenyuan Liu, Weihong Ge, Hua He, Qing Jiang   +4 more
doaj   +1 more source

Beyond Anticoagulant Exposure: Determinants of Mortality After Gastrointestinal Bleeding Across DOAC, Warfarin and Non‐Anticoagulated Patients

Alimentary Pharmacology &Therapeutics, EarlyView.
Among 11,387 patients with acute gastrointestinal bleeding, overlap‐weighted analyses (n = 10,044) found no statistically significant association between direct oral anticoagulant or warfarin use and 30‐day or 1‐year mortality. Haemodynamic shock was associated with 30‐day mortality, whereas age and Internal Medicine ward admission were associated with
Esther Forkosh, David Hakimian, Harold Jacob, Ian M. Gralnek, Lior Katz, Aviv Talmon   +5 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Edoxaban

, 2011
Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic ...
Camm, A John, A. John Camm, Henri Bounameaux, Bounameaux, Henri   +3 more
core   +1 more source